Therapeutic optimization of aromatase inhibitor-associated arthralgia: Etiology, onset, resolution, and symptom management in early breast cancer

Community Oncology

Volumn 9, Issue 3, 2012, Pages 94-102

  Jones, Cheryl ^a   Gilmore, James ^a   Saleh, Mansoor ^a   Feinberg, Bruce ^a   Kissner, Michelle ^b   Simmons, Stacey J ^b  

^a Georgia Cancer Specialists   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANASTROZOLE; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; CHONDROITIN SULFATE; CONJUGATED ESTROGEN; CYCLOOXYGENASE 2 INHIBITOR; DIURETIC AGENT; DOCETAXEL; EXEMESTANE; GLUCOSAMINE; GONADORELIN ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; LETROZOLE; LEUPRORELIN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROBIOTIC AGENT; TAMOXIFEN; TRAMADOL; UNINDEXED DRUG; VACCINE; VITAMIN D; VSL3;

ACUPRESSURE; ARTHRALGIA; ARTHROPATHY; BREAST CANCER; DISEASE DURATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY CANCER; EXERCISE; FOOT; GENETIC POLYMORPHISM; HAND; HIP; HUMAN; HYPERTHERMIC THERAPY; INCIDENCE; INFLAMMATION; JOINT STIFFNESS; KNEE; LABORATORY TEST; LIFESTYLE MODIFICATION; MASSAGE; MEDICAL HISTORY; MUSCULOSKELETAL DISEASE; MYALGIA; ORTHOPEDIC SHOE; PATIENT COUNSELING; PHYSIOTHERAPY; PREVALENCE; PROCESS OPTIMIZATION; QUALITY OF LIFE; RADIOGRAPHY; REVIEW; RISK REDUCTION; SHOULDER; STANDARDIZATION; STRETCHING EXERCISE; SYMPTOM; TENOSYNOVITIS; VAGINAL DRYNESS; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION; WRIST; YOGA;

EID: 84858434228     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cmonc.2012.02.005     Document Type: Review

References (38)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer v.2.2010. Available at: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed January 10, 2010.
2. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005; 23(3):619-629.
3. Ingle JN, Dowsett M, Cuzick J, Davies C. Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies. Cancer Res. 2009;69:12. doi:10.1158/0008-5472.SABCS-12.
4. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509-518.
5. Henry NL, Giles JT, Stearns V. Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management. Oncology (Williston Park). 2008;22(12):1401-1408.
6. Younus J, LKligman L. Management of aromatase inhibitorinduced arthralgia. Curr Oncol. 2010;17(1):87-90.
7. Gaillard S, Stearns V. Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res. 2011;13(2):205.
8. Chlebowski RT. Aromatase inhibitor-associated arthralgias. J Clin Oncol. 2009;27(30):4932-4934.
9. Din OS, Dodwell D, Winter MC, Mori S, Coleman RE. Current opinion of aromatase inhibitor-induced arthralgia in breast cancer in the UK. Clin Oncol (R Coll Radiol). 2011;23 (10):674-680.
10. Buzdar AU; ATAC Trialist' Group. Clinical features of joint symptoms observed in the 'Arimedex,' Tamoxifen, Alone or in Combination (ATAC) trial [ASCO abstract 551]. J Clin Oncol. 2006;24(18S, pt 1)(suppl.).
11. Presant CA, Bosserman L, Young T, et al. Aromatase inhibitorassociated arthralgia and/or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer. 2007;7(10):775-778.
12. Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol. 2010;73(2):156-166.
13. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26(4): 556-562.
14. Ziller V, Kalder N, Albert US, et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol. 2009;20(3):431-436.
15. Coleman RE, Bolten WW, Lansdown M, et al. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev. 2008;34(3):275-282.
16. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-3883.
17. Sestak I, Cuzick J, Sapunar F, et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol. 2008;9(9):866-872.
18. Mao JJ, Stricker C, Bruner D, et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer. 2009;115(16):3631-3639.
19. Kanematsu M, Morimoto M, Honda J, et al. The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia. BMC Cancer. 2011;11:436.
20. Thorne C. Management of arthralgias associated with aromatase inhibitor therapy. Curr Oncol. 2007;14(suppl 1): S11-S19.
21. Goodwin MA. Arthralgia, excerpt from: The 10-Minute Diagnosis Manual: Symptoms and Signs in the Time-Limited Encounter, R.B. Taylor (ed), Lippincott Williams & Wilkins: Philadelphia (2008; originally published 2000). Available at: http://www.wrongdiagnosis. com/a/arthritis/book-diseases-10a.htm. Accessed January 10, 2010.
22. Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol. 2007;25(25):3797-3799.
23. Henry NL, Jacobson J, Banerjee M, et al. Association of aromatase inhibitor-associated musculoskeletal symptoms with ultrasonographic changes at the wrist. Poster presented at: 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX; Abstract 802.
24. Morales L, Pans S, Paridaens R, et al. Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat. 2007;104(1):87-91.
25. Morales L, Pans S, Verschueren K, et al. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol. 2008; 26(19):3147-3152.
26. Henry NL, Jacobson JA, Banerjee M, et al. A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography. Cancer. 2010; 116(18):4360-4367.
27. Xepapadakis G, Ntasiou P, Koronarchis D, et al. New views on treatment of aromatase inhibitors induced arthralgia. Breast. 2010;19(3): 249-250.
28. Shanmugam VK, McCloskey J, Elston B, Allison SJ, Eng-Wong J. The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms. Breast Cancer Res Treat. 2012;131(2):699-708.
29. National Cancer Institute. Common Terminology Criteria for Adverse Events, version 4.0. Available at: http://safetyprofiler-ctep. nci.nih.gov/CTC/CTC.aspx. Accessed January 10, 2010.
30. Buzdar AU. Clinical features of joint symptoms observed in the 'Arimedex', Tamoxifen, Alone or in Combination (ATAC) trial. Poster presented at: 42nd Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2006; Atlanta, GA; Abstract 551.
31. Mackey J, Gelmon K. Adjuvant aromatase inhibitors in breast cancer therapy: significance of musculoskeletal complications. Curr Opin Oncol. 2007;19:S9-S18.
32. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al; The BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361(8)766-776.
33. Crew KD, Podolanczuk A, Brafman L, Awad D, Hershman DL. Prospective evaluation of joint symptoms in postmenopausal women initiating aromatase inhibitors for early breast cancer. Poster presented at: 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX; Abstract 5044.
34. Henry NL, Giles JT, Ang D, et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat. 2008;111(2):365-372.
35. Felson DT, Cummings SR. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum. 2005; 52(9):2594-2598.
36. DinOS, Dodwell D, Wakefield RJ, Coleman RE. Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more? Breast Cancer Res Treat. 2010;120(3):525-538.
37. Josse RG. Roles for estrogen in bone loss and arthralgia during aromatase inhibitor treatment. Curr Opin Oncol. 2007;19:S1-S8. doi: 10.1097/01.cco.0000266465.24079.63.
38. Ingle JN, Schaid DJ, Goss PE, et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol. 2010;28(31):4674-4682.